Most people diagnosed with mesothelioma still die from it.
Decades of asbestos regulation have bent the curve of mesothelioma risk downward, yet the disease continues to claim more American lives in absolute terms than it did a generation ago — a paradox born of population growth, aging, and the long biological memory of industrial exposure. A sweeping 33-year analysis from the University of Miami finds that what kills people today often traces back to what they breathed in the 1970s and 1980s, when asbestos was still woven into the fabric of American industry. The burden is not fading evenly: women, and residents of states shaped by shipbuilding, mining, and heavy construction, are being left behind by prevention frameworks designed for a different era. The data ask a quiet but insistent question — how long must a society live with the consequences of a hazard it has not yet fully renounced?
- Despite a one-third drop in age-adjusted risk over 33 years, absolute mesothelioma diagnoses and deaths have climbed nearly 30 percent as the U.S. population grows older and larger — the headline progress conceals a deepening burden.
- The mortality-to-incidence ratio has held near one for the entire study period, meaning that for most of the three decades examined, a mesothelioma diagnosis has remained effectively a death sentence regardless of therapeutic advances.
- Women are emerging as a population the old occupational-exposure model cannot explain — incidence is rising in 20 states and mortality in 18, pointing toward environmental, household, and para-occupational pathways that current prevention strategies largely ignore.
- Maine, Alaska, Washington, and Minnesota carry disproportionate burdens tied to shipyards, mineral mining, and naturally occurring asbestos, revealing that national averages mask urgent, place-specific crises.
- With 96 percent of 2023 deaths still attributable to occupational asbestos exposure and no comprehensive U.S. ban in place, researchers are calling for simultaneous investment in remediation and in the therapeutic breakthroughs that have so far failed to move survival rates at scale.
The numbers present a paradox. Over 33 years, the age-adjusted rate of mesothelioma in the United States has fallen by roughly one-third, and asbestos regulations have tightened. Yet the absolute number of Americans diagnosed has climbed nearly 30 percent, deaths continue to rise, and the disability burden has grown 14 percent since 1990. A new analysis from Sylvester Comprehensive Cancer Center at the University of Miami, tracking cases across all 50 states from 1990 to 2023, reveals a disease that is not fading — it is shifting, concentrating, and affecting populations that older prevention frameworks never anticipated.
Mesothelioma operates like a time capsule. Its latency can stretch decades, meaning that what kills someone today often reflects an exposure from the 1970s or 1980s — an era of shipbuilding, factory insulation, and asbestos-wrapped infrastructure. The falling rate per person masks a harder truth: because the population has grown and aged, more people are being diagnosed and dying even as individual risk declines. Survival has barely moved. The mortality-to-incidence ratio has remained stubbornly near one across the entire study period, and even newer immunotherapies have not yet shifted outcomes at a national scale.
The widening gap between men and women is among the study's starkest findings. Male incidence and mortality have fallen sharply, reflecting the aging out of cohorts who worked in heavily exposed occupations. Among women, declines have been modest or statistically insignificant, with incidence rising in 20 states and mortality climbing in 18, particularly across the Midwest and Appalachia. This divergence points toward environmental exposure, para-occupational contact — asbestos carried home on a family member's clothing — and legacy fibers embedded in schools, homes, and public buildings.
Geography remains destiny. Maine, Alaska, Washington, and Minnesota consistently show the highest burdens, each shaped by distinct industrial and geological histories: coastal shipyards, iron ore mining, construction-disturbed asbestos deposits. National averages smooth over these place-based concentrations, obscuring where prevention and remediation are most urgently needed. Nearly 96 percent of 2023 deaths remain attributable to occupational exposure — a proportion virtually unchanged since 1990 — reflecting both the persistence of asbestos in older infrastructure and the United States' incomplete ban on its use.
The researchers conclude that reducing mesothelioma's future toll demands both halves of an equation: sustained remediation and environmental protection, alongside genuine investment in more effective treatments. The disease is overwhelmingly preventable, yet prevention remains unfinished. For clinicians, the data urge heightened awareness in women and in patients without obvious workplace histories. For the rest of us, mesothelioma is a reminder that the consequences of exposure can outlast entire generations — and so can the responsibility to those still living with them.
The numbers tell a story of paradox. Over the past three decades, the age-adjusted rate of mesothelioma in the United States has fallen by roughly one-third. Asbestos regulations have tightened. Industrial use has declined. And yet, the absolute number of Americans diagnosed with this rare cancer has climbed by nearly 30 percent, and deaths continue to mount. A new analysis from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, tracking mesothelioma cases across all 50 states from 1990 to 2023, reveals a disease that refuses to fade into history—one that is instead shifting, concentrating in new places, and affecting populations in ways that older prevention frameworks never anticipated.
Mesothelioma is often spoken of as a relic, a disease born from an earlier industrial age when asbestos lined ships, insulated factories, and wrapped around the bones of American infrastructure. But the new study, published in JCO Global Oncology, shows something more unsettling: the disease persists not because exposures are happening now at the scale they once did, but because exposures from 30 or 40 years ago are still claiming lives. The cancer operates like a time capsule, with latency periods that can stretch decades. What kills someone today often reflects what they breathed in an era most of us have forgotten.
The falling rates, when examined closely, mask a harder truth. Because the U.S. population has grown and aged, more people are being diagnosed and more are dying, even as the risk per person has declined. The disability burden—measured in disability-adjusted life years—has risen 14 percent since 1990. Survival has barely budged. The mortality-to-incidence ratio, a measure of how many people diagnosed actually die from the disease, has remained stubbornly near one across the entire 33-year period. Most people diagnosed with mesothelioma still die from it. Even the arrival of newer therapies, including immune checkpoint inhibitors, has not yet shifted outcomes at a national scale.
What emerges most starkly from the data is a widening gap between men and women. Among men, both incidence and mortality rates have fallen sharply, reflecting the gradual aging out of cohorts who worked in shipbuilding, construction, and insulation—occupations where asbestos exposure was routine and well-documented. Among women, the picture is far different. Declines have been modest and often statistically insignificant. In 20 states, female incidence has actually increased. In 18 states, female mortality has risen, particularly across the Midwest and Appalachia. This divergence points toward exposure pathways that do not fit the traditional occupational narrative. For women, mesothelioma often arrives without a clear workplace history. Environmental exposure, para-occupational exposure from family members who brought asbestos home on their clothes, and legacy asbestos embedded in schools, homes, and public buildings likely account for much of this burden.
Geography remains destiny. Maine, Alaska, Washington, and Minnesota consistently show the highest incidence, mortality, and disability burdens. Each state's story is distinct: shipyards along both coasts, naturally occurring asbestos disturbed during construction, mineral fibers tied to iron ore mining. National averages obscure these place-based risks. The map of mesothelioma in America looks less like a smooth gradient and more like a patchwork, stitched together by local industry, geology, and the long shadow of history. State-level data reveal where prevention and remediation efforts are most urgently needed—and where they have been most neglected.
Perhaps the most sobering finding is what has not changed. Nearly 96 percent of mesothelioma deaths in 2023 remain attributable to occupational asbestos exposure, a proportion virtually unchanged since 1990. This persistence reflects two realities: asbestos is still embedded in older buildings, ships, and infrastructure across the country, and the United States has never fully banned its use. Remediation efforts continue, but they are incomplete and uneven. The disease is overwhelmingly preventable, yet prevention remains incomplete.
The researchers argue that reducing mesothelioma's future burden will require both halves of an equation: continued vigilance in asbestos remediation and environmental protection, alongside sustained investment in more effective treatments. Prevention and treatment are inseparable. The challenge is not to accept mesothelioma as a fading echo of the past, but to recognize it as an evolving disease, shaped by legacy exposures and modern inequities, concentrated in specific places and among specific populations. For clinicians, the message is to maintain awareness of mesothelioma in women and in patients without obvious occupational exposure. For researchers, the persistently high fatality rates signal an urgent need for therapeutic breakthroughs. The disease reminds us that the consequences of exposure can last a lifetime—and so can our responsibility to those affected.
Notable Quotes
Mesothelioma behaves like a time capsule. What we're seeing today reflects exposures that happened 30 or 40 years ago, and in some cases, exposures that are still happening in quieter, less visible ways.— Chinmay Jani, M.D., chief fellow at Sylvester Comprehensive Cancer Center
For women, mesothelioma often doesn't come with a neat occupational history. Environmental exposure, para-occupational exposure from family members and legacy asbestos in schools, homes and public buildings likely play a much larger role.— Estelamari Rodriguez, M.D., M.P.H., clinical research lead at Sylvester
The Hearth Conversation Another angle on the story
Why does the study call this a paradox? Aren't falling rates good news?
Falling rates per person are good news. But the absolute number of cases and deaths keeps climbing because the population is growing and aging. It's like saying the percentage of people getting sick went down, but more people are actually sick. The math works, but the human impact doesn't improve.
So these are mostly old exposures—people who were exposed decades ago?
Exactly. Mesothelioma has a latency period of 20 to 50 years. What we're seeing today is largely the tail end of industrial exposures from the 1970s and 1980s. But the disease is also still being caused by asbestos that's embedded in buildings, schools, and homes right now.
Why are women's numbers going up when men's are going down?
Men's exposures were mostly occupational—shipyards, construction, insulation work. Those jobs have changed or disappeared. Women are being exposed differently: through environmental asbestos in their homes and communities, or through secondary exposure when family members brought asbestos dust home on their clothes. Those pathways are harder to see and harder to prevent.
Which states are hit hardest?
Maine, Alaska, Washington, and Minnesota. Each has a different reason—shipyards, naturally occurring asbestos, mining. But the point is that national averages hide these concentrations. If you live in Maine, your risk is much higher than the national average suggests.
Has treatment gotten better?
New drugs have arrived, but they haven't moved the needle at a population level yet. The mortality-to-incidence ratio is still near one, meaning most people diagnosed still die from it. That's the hardest message: despite scientific advances, mesothelioma remains one of the most lethal solid tumors.
What would actually reduce this burden?
Two things together: keep people from being exposed in the first place, and develop better treatments for those who are. The U.S. has never fully banned asbestos, so there's still asbestos in buildings. Remediation is incomplete. And we need breakthroughs in therapy. Neither alone is enough.